The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback